Labcorp (LH) — insider trading
Health Care · NYSE
Labcorp (LH) has 42 reported SEC Form 4 insider transactions in our data, including 10 open-market sales among the most recent 42 (latest 2026-09-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | Oyegunwa Akinbolade | Officer (EVP, CIO & CTO) | Grant / award / vesting (derivative) | 750 | — | $0 | Form 4 |
| 2026-09-01 | Meltzer Jonathan C | Officer (EVP, COO) | Grant / award / vesting (derivative) | 900 | — | $0 | Form 4 |
| 2026-09-01 | Vaughn Bryan T | Officer (EVP and President, Diagnostics) | Grant / award / vesting (derivative) | 1,500 | — | $0 | Form 4 |
| 2026-09-01 | Caveney Brian J | Officer (EVP, Pres of BLS, CMO & CSO) | Grant / award / vesting (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-08-17 | ANDERSON KERRII B | Director | Open-market sale | 3,000 | $318.02 | $954.1K | Form 4 |
| 2026-08-11 | Schechter Adam H | Director, Officer (President & CEO) | Open-market sale | 4,669 | $320.37 | $1.50M | Form 4 |
| 2026-08-04 | Summy Amy B. | Officer (EVP, Chief Marketing Officer) | Open-market sale | 924 | $306.74 | $283.4K | Form 4 |
| 2026-08-03 | Wilkinson Peter J | Officer (SVP, Chief Accounting Officer) | Option exercise / conversion (derivative) | 1,338 | — | $0 | Form 4 |
| 2026-08-03 | Wilkinson Peter J | Officer (SVP, Chief Accounting Officer) | Open-market sale | 1,338 | $309.23 | $413.8K | Form 4 |
| 2026-08-03 | Wilkinson Peter J | Officer (SVP, Chief Accounting Officer) | Option exercise / conversion | 1,338 | $209.25 | $280.0K | Form 4 |
| 2026-08-03 | Wilkinson Peter J | Officer (SVP, Chief Accounting Officer) | Open-market sale | 82 | $309.22 | $25.4K | Form 4 |
| 2026-07-02 | Vaughn Bryan T | Officer (EVP and President, Diagnostics) | Open-market sale | 234 | $286.19 | $67.0K | Form 4 |
| 2026-07-02 | Kyle Kathryn W | Officer (EVP, Chief Legal Officer) | Open-market sale | 92 | $286.19 | $26.3K | Form 4 |
| 2026-07-01 | Vaughn Bryan T | Officer (EVP and President, Diagnostics) | Option exercise / conversion (derivative) | 327 | — | $0 | Form 4 |
| 2026-07-01 | Vaughn Bryan T | Officer (EVP and President, Diagnostics) | Shares withheld for taxes / exercise cost | 93 | $283.88 | $26.4K | Form 4 |
| 2026-07-01 | Vaughn Bryan T | Officer (EVP and President, Diagnostics) | Option exercise / conversion | 327 | — | — | Form 4 |
| 2026-07-01 | Kyle Kathryn W | Officer (EVP, Chief Legal Officer) | Option exercise / conversion (derivative) | 256 | — | $0 | Form 4 |
| 2026-07-01 | Kyle Kathryn W | Officer (EVP, Chief Legal Officer) | Shares withheld for taxes / exercise cost | 73 | $283.88 | $20.7K | Form 4 |
| 2026-07-01 | Kyle Kathryn W | Officer (EVP, Chief Legal Officer) | Option exercise / conversion | 256 | — | — | Form 4 |
| 2026-06-08 | Kyle Kathryn W | Officer (EVP, Chief Legal Officer) | Open-market sale | 762 | $263.89 | $201.1K | Form 4 |
| 2026-05-11 | Schechter Adam H | Director, Officer (President & CEO) | Open-market sale | 5,903 | $254.50 | $1.50M | Form 4 |
| 2026-03-27 | Wilkinson Peter J | Officer (SVP, Chief Accounting Officer) | Open-market sale | 1,633 | $267.05 | $436.1K | Form 4 |
| 2026-03-26 | Summy Amy B. | Officer (EVP, Chief Marketing Officer) | Shares withheld for taxes / exercise cost | 1,836 | $268.38 | $492.7K | Form 4 |
| 2026-03-26 | Summy Amy B. | Officer (EVP, Chief Marketing Officer) | Grant / award / vesting | 3,994 | — | $0 | Form 4 |
| 2026-03-26 | van der Vaart Sandra D | Officer (EVP, Corporate Affairs) | Shares withheld for taxes / exercise cost | 2,722 | $268.38 | $730.5K | Form 4 |
| 2026-03-26 | van der Vaart Sandra D | Officer (EVP, Corporate Affairs) | Grant / award / vesting | 6,382 | — | $0 | Form 4 |
| 2026-03-26 | Vaughn Bryan T | Officer (EVP, Diagnostics) | Shares withheld for taxes / exercise cost | 451 | $268.38 | $121.0K | Form 4 |
| 2026-03-26 | Vaughn Bryan T | Officer (EVP, Diagnostics) | Grant / award / vesting | 1,584 | — | $0 | Form 4 |
| 2026-03-26 | Wilkinson Peter J | Officer (SVP, Chief Accounting Officer) | Shares withheld for taxes / exercise cost | 755 | $268.38 | $202.6K | Form 4 |
| 2026-03-26 | Wilkinson Peter J | Officer (SVP, Chief Accounting Officer) | Grant / award / vesting | 2,388 | — | $0 | Form 4 |
| 2026-03-26 | Caveney Brian J | Officer (EVP, Pres of ED, CMO & CSO) | Shares withheld for taxes / exercise cost | 863 | $268.38 | $231.6K | Form 4 |
| 2026-03-26 | Caveney Brian J | Officer (EVP, Pres of ED, CMO & CSO) | Grant / award / vesting | 1,986 | — | $0 | Form 4 |
| 2026-03-26 | Caveney Brian J | Officer (EVP, Pres of ED, CMO & CSO) | Shares withheld for taxes / exercise cost | 4,042 | $268.38 | $1.08M | Form 4 |
| 2026-03-26 | Caveney Brian J | Officer (EVP, Pres of ED, CMO & CSO) | Grant / award / vesting | 9,304 | — | $0 | Form 4 |
| 2026-03-26 | Schroeder Mark S | Officer (EVP, Pres Diagnostics & COO) | Shares withheld for taxes / exercise cost | 1,468 | $268.38 | $394.0K | Form 4 |
| 2026-03-26 | Schroeder Mark S | Officer (EVP, Pres Diagnostics & COO) | Grant / award / vesting | 2,968 | — | $0 | Form 4 |
| 2026-03-26 | Schroeder Mark S | Officer (EVP, Pres Diagnostics & COO) | Shares withheld for taxes / exercise cost | 4,600 | $268.38 | $1.23M | Form 4 |
| 2026-03-26 | Schroeder Mark S | Officer (EVP, Pres Diagnostics & COO) | Grant / award / vesting | 9,304 | — | $0 | Form 4 |
| 2026-03-26 | GRAHAM ANITA Z | Officer (EVP, CHRO) | Shares withheld for taxes / exercise cost | 2,879 | $268.38 | $772.7K | Form 4 |
| 2026-03-26 | GRAHAM ANITA Z | Officer (EVP, CHRO) | Grant / award / vesting | 6,604 | — | $0 | Form 4 |
| 2026-03-26 | Schechter Adam H | Director, Officer (President & CEO) | Shares withheld for taxes / exercise cost | 26,106 | $268.38 | $7.01M | Form 4 |
| 2026-03-26 | Schechter Adam H | Director, Officer (President & CEO) | Grant / award / vesting | 58,470 | — | $0 | Form 4 |
Ask the chat about LH's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Labcorp (LH).
Last updated 2026-09-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.